Back to Index

Kadmon Corporation Presents Encouraging Nonclinical Data on Tesevatinib (KD019) at AACR Annual Meeting

-- Data Support Potential of Tesevatinib in Treating Gliomas and Brain Metastases --

PHILADELPHIA, April 20, 2015 – Kadmon Corporation, LLC, today announced nonclinical data demonstrating the potential of tesevatinib (formerly known as KD019), the company’s Phase 2 tyrosine kinase inhibitor, for the treatment of gliomas and cancers that have metastasized to the brain. The data will be presented today in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia.

Tesevatinib selectively inhibits a specific combination of established therapeutic targets in cancer: EGFR, HER2, VEGFR2/3 and Src family kinases. Importantly, tesevatinib has shown in nonclinical models to cross the blood-brain barrier, a critical shortcoming of current targeted therapies that limits their ability to reach and effectively treat intracranial tumors. The data presented demonstrate that tesevatinib is highly blood-brain barrier penetrant, achieving concentrations in the brain that are greater than or equivalent to levels achieved in the blood. Furthermore, the data show that tesevatinib inhibits intracranial tumor growth in mice.

“Tesevatinib is widely distributed outside the blood and accumulates in tissues, including the brain, aiding in the targeting of cancer cells,” said James Tonra, Ph.D., Senior Vice President, Nonclinical Development at Kadmon and first author of the abstract. “The data support the study of tesevatinib in additional experiments aimed at benefiting patients with intracranial tumors.”

“Treatment for central nervous system tumors represents a major medical need, as current targeted therapies cannot effectively cross the blood-brain barrier,” said Harlan W. Waksal, M.D., President and CEO of Kadmon. “Tesevatinib’s unique profile of kinase activity and brain penetrance in nonclinical models support the rationale for clinical testing in our ongoing Phase 1b/2a trial in HER2+ breast cancer with brain metastases as well as our planned clinical study in glioblastoma.”

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

About Kadmon Corporation
Kadmon Corporation, LLC, is a biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology, monogenic diseases and metabolic disease. For more information, visit

Contact Information
Ellen Tremaine, Investors